Atara Biotherapeutics, Inc

ATRANASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
8.39 USD
↘ 0.33 (3.78%)AT CLOSE (11:59 AM EDT)
8.42
↗ 0.03 (0.36%)
POST MARKET (AS OF 07:17 PM EDT)
Post Market
AS OF 07:17 PM EDT
8.42
↗ 0.03 (0.36%)
🔴Market: CLOSED

Atara Biotherapeutics, Inc (ATRA) trades at $8.48 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, exceptional Return on Equity (25.4%) and a bearish Death Cross on the long-term moving averages. Valuation metrics place ATRA at a fair price relative to peers.

Technical & fundamental data as of Jul 17, 2026.

Open?$8.24
High?$8.82
Low?$8.10
Prev. Close?$8.72
Volume?81.3K
Avg. Volume?87.3K
VWAP?$8.52
Rel. Volume?0.93x
Bid / Ask
Bid?$7.02 × 100
Ask?$11.18 × 100
Spread?$4.16
Midpoint?$9.10
Valuation & Ratios
Market Cap?78.6M
Shares Out?9.0M
Float?2.6M
Float %?36.0%
P/E Ratio?N/A
P/B Ratio?-2.11
EPS?-$1.05
Dividend?0.00%
Ex-Dividend?N/A
RelatedORIC
News
Profile
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Immunology & Autoimmune
Employees
13
Market Cap
78.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.atarabio.com
Listed
2014-10-16
Address
1280 RANCHO CONEJO BLVD
THOUSAND OAKS, CA 91320
Phone: 805-623-4211
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
2
Short Sent.?
70
Piotroski F-Score?1/9Weak
Altman Z-Score?-140.51Distress
Confidence?50%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?13.95%High
Short Interest?361.5K
Days to Cover?4.0
Free Float2.6M
Avg Daily Volume91.5K
Settlement Date2026-06-30
Financial Health
Current Ratio?2.16Strong
Quick Ratio?2.16Strong
Cash Ratio?1.48Strong
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
-2.11CHEAP▾
P/S?
S&P
45
3.40FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-11.8CHEAP▾
EV/Sales?
S&P
60
3.03FAIR▾
Returns & Efficiency
ROE?
S&P
74
25.4%STRONG▾
ROA?
S&P
3
-47.3%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$70.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist